levofloxacin has been researched along with Black Death in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deziel, MR; Drusano, GL; Liu, W; Louie, A | 1 |
| Butler, T | 1 |
| Campbell, JL; Hewitt, JA; Lanning, LL | 1 |
| Campbell, JL; Fay, MP; Hewitt, JA; Lanning, LL | 1 |
| Anisimov, BI; Ryzhko, IV; Trishina, AV; Tsuraeva, RI | 1 |
| Barr, EB; Brasel, TL; Gigliotti, AP; Koster, F; Layton, RC; McDonald, JD; Mega, W | 1 |
| Ryzhko, IV; Trishina, AV; Verkina, LM | 1 |
| Brackman, SM; Chopra, AK; Erova, TE; Kirtley, ML; Peterson, JW; Rosenzweig, JA; Sha, J; Xu, ZQ; Yeager, LA | 1 |
| Chopra, AK; Erova, TE; Fitts, EC; Kirtley, ML; Kozlova, EV; Rosenzweig, JA; Sha, J; Tiner, BL; van Lier, CJ | 1 |
| Chopra, AK; Erova, TE; Kirtley, ML; Motin, VL; Rosenzweig, JA; Sha, J; Sierra, JC; Suarez, G; Telepnev, MV; van Lier, CJ | 1 |
| Bassett, J; Drusano, GL; Heine, HS; Kinzig-Schippers, M; Louie, A; Miller, L; Sorgel, F; Sullivan, LJ | 1 |
| Agar, SL; Baze, WB; Chauhan, S; Chopra, AK; Erova, TE; Fadl, AA; Foltz, SM; Klimpel, GR; Motin, VL; Olano, JP; Peterson, JW; Sha, J; Suarez, G; Wang, S | 1 |
12 other study(ies) available for levofloxacin and Black Death
| Article | Year |
|---|---|
Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Drug Resistance, Bacterial; Humans; Immunocompetence; Levofloxacin; Mice; Microbial Sensitivity Tests; Mutation; Neutropenia; Ofloxacin; Plague; Selection, Genetic; Streptomycin; Thigh; Treatment Outcome; Yersinia pestis | 2007 |
Plague Gives Surprises in the Second Decade of the Twenty-First Century.
Topics: Animals; Anti-Bacterial Agents; Chlorocebus aethiops; Humans; Levofloxacin; Male; Plague; Sciuridae; Yersinia pestis | 2023 |
The African Green Monkey Model of Pneumonic Plague and US Food and Drug Administration Approval of Antimicrobials Under the Animal Rule.
Topics: Animals; Chlorocebus aethiops; Disease Models, Animal; Levofloxacin; Plague; United States; United States Food and Drug Administration; Yersinia pestis | 2020 |
Effect of Delaying Treatment on Efficacy of Ciprofloxacin and Levofloxacin in the African Green Monkey Model of Pneumonic Plague.
Topics: Animals; Anti-Bacterial Agents; Chlorocebus aethiops; Ciprofloxacin; Disease Models, Animal; Levofloxacin; Plague; Yersinia pestis | 2020 |
[Efficacy of levofloxacin, lomefloxacin and moxifloxacin vs. other fluoroquinolones in experimental plague due to FI+ and FI- strains of Yersinia pestis in Albino mice].
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Mice; Moxifloxacin; Ofloxacin; Plague; Quinolines; Species Specificity; Time Factors; Yersinia pestis | 2009 |
Levofloxacin cures experimental pneumonic plague in African green monkeys.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Chlorocebus aethiops; Disease Models, Animal; Infusions, Intravenous; Levofloxacin; Lung; Ofloxacin; Plague; Primate Diseases; Radiography, Thoracic; Survival Analysis | 2011 |
[Lack of levofloxacin and moxyfloxacin efficacy in experimental plague of albino mice infected with nalidixic acid resistant pathogen (Nal(r))].
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Lethal Dose 50; Levofloxacin; Mice; Models, Animal; Nalidixic Acid; Ofloxacin; Plague; Virulence; Yersinia pestis | 2010 |
Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.
Topics: Animals; Anti-Bacterial Agents; Female; Ketolides; Levofloxacin; Ofloxacin; Plague; Rats; Yersinia pestis | 2011 |
A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague.
Topics: Animals; Animals, Outbred Strains; Anti-Bacterial Agents; Disease Models, Animal; Female; Flow Cytometry; Genes, Reporter; Humans; Levofloxacin; Luciferases; Mice; Microscopy, Fluorescence; Molecular Imaging; Ofloxacin; Plague; Virulence; Yersinia pestis | 2013 |
Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.
Topics: Animals; Antibodies, Bacterial; Bacterial Outer Membrane Proteins; Bacterial Proteins; Immune Sera; Immunization; Immunization, Passive; Levofloxacin; Mice; Ofloxacin; Plague; Plague Vaccine; Plasminogen Activators; Rats; Recombinant Proteins; Vaccines, Synthetic; Virulence Factors; Yersinia pestis | 2013 |
Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Topics: Aerosols; Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Doxycycline; Female; Gentamicins; Levofloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Neutropenia; Ofloxacin; Plague; Protein Biosynthesis; Time Factors; Yersinia pestis | 2007 |
Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague.
Topics: Animals; Anti-Bacterial Agents; Cytokines; Disease Models, Animal; Female; Levofloxacin; Lipoproteins; Macrophages; Mice; Mice, Inbred BALB C; Mutation; Ofloxacin; Plague; Virulence; Virulence Factors; Yersinia pestis; Yersinia pseudotuberculosis | 2008 |